.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Dow
Baxter
Medtronic
Federal Trade Commission
Johnson and Johnson
QuintilesIMS
Fuji
Chubb
Cantor Fitzgerald

Generated: December 12, 2017

DrugPatentWatch Database Preview

Genzyme Corp Company Profile

« Back to Dashboard

What is the competitive landscape for GENZYME CORP, and when can generic versions of GENZYME CORP drugs launch?

GENZYME CORP has five approved drugs.

There are five US patents protecting GENZYME CORP drugs.

There are one hundred and thirteen patent family members on GENZYME CORP drugs in thirty-nine countries and nineteen supplementary protection certificates in twelve countries.

Summary for Genzyme Corp

International Patents:113
US Patents:5
Tradenames:4
Ingredients:4
NDAs:5
Drug Master File Entries: 5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Genzyme CorpHECTOROLdoxercalciferolCAPSULE;ORAL020862-002Apr 23, 2004ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Genzyme CorpCERDELGAeliglustat tartrateCAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genzyme CorpFLUDARAfludarabine phosphateINJECTABLE;INJECTION020038-001Apr 18, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Genzyme CorpCERDELGAeliglustat tartrateCAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Genzyme CorpCERDELGAeliglustat tartrateCAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Genzyme CorpCERDELGAeliglustat tartrateCAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Genzyme Corp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme CorpHECTOROLdoxercalciferolCAPSULE;ORAL020862-001Jun 9, 1999► Subscribe► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-002Apr 6, 2011► Subscribe► Subscribe
Genzyme CorpCAPRELSAvandetanibTABLET;ORAL022405-001Apr 6, 2011► Subscribe► Subscribe
Genzyme CorpHECTOROLdoxercalciferolCAPSULE;ORAL020862-002Apr 23, 2004► Subscribe► Subscribe
Genzyme CorpFLUDARAfludarabine phosphateINJECTABLE;INJECTION020038-001Apr 18, 1991► Subscribe► Subscribe
Genzyme CorpHECTOROLdoxercalciferolINJECTABLE;INJECTION021027-002Apr 6, 2000► Subscribe► Subscribe
Genzyme CorpHECTOROLdoxercalciferolCAPSULE;ORAL020862-001Jun 9, 1999► Subscribe► Subscribe
Genzyme CorpHECTOROLdoxercalciferolCAPSULE;ORAL020862-001Jun 9, 1999► Subscribe► Subscribe
Genzyme CorpHECTOROLdoxercalciferolINJECTABLE;INJECTION021027-001Apr 6, 2000► Subscribe► Subscribe
Genzyme CorpHECTOROLdoxercalciferolCAPSULE;ORAL020862-001Jun 9, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GENZYME CORP drugs

Drugname Dosage Strength Tradename Submissiondate
doxercalciferolInjection2 mcg/mL, 1 mL in 2 mL vialHECTOROL12/28/2011
doxercalciferolCapsules1 mcgHECTOROL2/12/2010
doxercalciferolCapsules0.5 mcg and 2.5 mcgHECTOROL3/25/2009
doxercalciferolInjection2 mcg/mL, 2 mL ampulesHECTOROL10/15/2007

Non-Orange Book Patents for Genzyme Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,255,336 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
8,779,163Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
7,265,228Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
5,916,911 Amino ceramide--like compounds and therapeutic methods of use► Subscribe
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,897,210 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,569,889 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
7,763,738Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
6,890,949 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,673,803 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genzyme Corp Drugs

Country Document Number Estimated Expiration
Australia4561397► Subscribe
Portugal2067775► Subscribe
Argentina049059► Subscribe
China1142920► Subscribe
South Africa200609110► Subscribe
European Patent Office1196406► Subscribe
Denmark1753431► Subscribe
Norway20065735► Subscribe
European Patent Office1409467► Subscribe
Japan5038582► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genzyme Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0048France► SubscribePRODUCT NAME: VANDETANIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/11/749/002 20120217
2012015Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
2015 00035Denmark► SubscribePRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119
12/029Ireland► SubscribePRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
C0036France► SubscribePRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119
90029-3Sweden► SubscribePRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121
15/027Ireland► SubscribePRODUCT NAME: ELIGLUSTAT, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/14/974 20150119
00543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
/2015Austria► SubscribePRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
0543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Teva
QuintilesIMS
Citi
Cipla
US Department of Justice
Accenture
Boehringer Ingelheim
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot